<DOC>
	<DOCNO>NCT00527020</DOCNO>
	<brief_summary>GSK1018921 new drug development treatment schizophrenia . GSK1018921 differs available drug mode action assume may effect treatment so-called positive symptom hallucination negative symptom lack drive . No clinical study conduct GSK1018921 human . This first study compound administer human ; study 2 part : Part A dose escalation study , Part B pharmacodynamic portion separate group healthy smoker volunteer .</brief_summary>
	<brief_title>First Time Human Study With GSK1018921</brief_title>
	<detailed_description>Single-Blind , Randomised , Placebo-Controlled First Time Human Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Single Oral Escalating Doses GSK1018921 Healthy Volunteers assess effect single dose GSK1018921 quantitative EEG Mismatch Negativity separate cohort healthy smoker volunteer</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy volunteer determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . For Part B , smoker . Part A : Smokers , subject take prescribe nonprescribed medication/vitamins specify prohibit protocol , substance abuse , clinically significant disease determine responsible physician . Part B : NonSmokers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>qEEG</keyword>
	<keyword>GlyT-1 inhibitor</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>ERP</keyword>
	<keyword>FTIH</keyword>
	<keyword>MMN</keyword>
	<keyword>GSK1018921</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>single-dose</keyword>
</DOC>